MLH1 and neoplasm: Patients with higher levels of MLH1 also exhibited a survival advantage, with elevated levels of MLH1 mRNA present in tumours from women who lived longer than 7 years after diagnosis, compared with women who lived for <3 years after diagnosis (P=0.0005, 95% confidence interval, 0.15–0.52), as shown in Figure 1A, bottom panel.